普莱柯所属申万行业为：农林牧渔-动物保健Ⅱ-动物保健Ⅲ。所属概念板块包括：动物疫苗、禽流感药 物、知识产权、宠物经济、小盘等。 截至6月30日，普莱柯股东户数1.80万，较上期增加4.27%；人均流通股19234股，较上期减少4.09%。 2025年1月-6月，普莱柯实现营业收入5.59亿元，同比增长15.79%；归母净利润1.16亿元，同比增长 57.12%。 分红方面，普莱柯A股上市后累计派现10.57亿元。近三年，累计派现5.00亿元。 机构持仓方面，截止2025年6月30日，普莱柯十大流通股东中，国泰中证畜牧养殖ETF（159865）位居 第七大流通股东，持股344.99万股，相比上期增加14.14万股。 责任编辑：小浪快报 9月8日，普莱柯盘中上涨2.01%，截至09:53，报14.74元/股，成交2765.57万元，换手率0.55%，总市值 51.01亿元。 资金流向方面，主力资金净流入102.68万元，特大单买入156.68万元，占比5.67%，卖出0.00元，占比 0.00%；大单买入474.59万元，占比17.16%，卖出528.59万元，占比19.11%。 普莱柯今年以来股价涨19.21% ...

发布时间：2025-09-03 股票投资评级 增持|维持 个股表现 -9% -4% 1% 6% 11% 16% 21% 26% 31% 36% 2024-09 2024-11 2025-01 2025-04 2025-06 2025-09 普莱柯 农林牧渔 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 14.63 | | --- | --- | | 总股本/流通股本（亿股）3.46 / 3.46 | | | 总市值/流通市值（亿元）51 / 51 | | | 52 周内最高/最低价 | 15.51 / 10.95 | | 资产负债率(%) | 15.2% | | 市盈率 | 54.19 | | 第一大股东 | 张许科 | 研究所 分析师:王琦 SAC 登记编号:S1340522100001 Email:wangqi2022@cnpsec.com 证券研究报告：农林牧渔 | 公司点评报告 普莱柯(603566) 业绩持续改善，禽苗及宠物相关产品收入增长明显 ⚫ 事件： 公司发布 2025 年中报，公司实现营业收入 5.59 亿元，同比增长 15.79%；归属于上市公司股东的净利润 1. ...

Core Viewpoint - The report highlights the strong performance of the pet segment and the impact of new product launches on the company's revenue growth, leading to an "overweight" rating for the company. Group 1: Financial Performance - In the first half of 2025, the company achieved operating revenue of 559 million yuan, a year-on-year increase of 15.79% [1] - The net profit attributable to shareholders reached 116 million yuan, up 57.12% year-on-year, while the net profit after deducting non-recurring gains and losses was 100 million yuan, reflecting a growth of 50.79% [1] - The net cash flow from operating activities was 195 million yuan, showing a significant increase of 305.09% year-on-year [1] - In Q2 2025, the company reported operating revenue of 281 million yuan, a year-on-year increase of 13.38%, and a net profit of 63 million yuan, up 35.67% year-on-year [1] Group 2: Product Performance - Revenue from various product segments in H1 2025 included: - Pig vaccines: 131 million yuan, down 11.49% year-on-year - Poultry vaccines and antibodies: 259 million yuan, up 30.01% year-on-year - Ruminant vaccines: 1.68 million yuan, up 39.62% year-on-year - Pet vaccines: 10.07 million yuan, up 49.65% year-on-year - Chemical drugs: 124 million yuan, up 20.94% year-on-year - Pet chemical drugs: 8.37 million yuan, up 9.99% year-on-year - Pet health products: 128.14 million yuan, up 124.47% year-on-year [2] - The new production base in Nanjing has been fully operational, leading to a nearly 60% increase in sales revenue from high-pathogenic avian influenza vaccines [2] - The company continues to implement a dual-channel marketing strategy for pet products, with online sales increasing by over three times [2] Group 3: Cost Control and R&D - The company's gross margin was 59.76%, a decrease of 3.42 percentage points year-on-year, while the net profit margin was 20.77%, down 5.47 percentage points year-on-year [3] - The company received 8 new veterinary drug registration certificates and 4 invention patent authorizations in H1 2025, indicating strong R&D capabilities [3] - Despite the decrease in margins, the company maintained a high level of R&D investment while enhancing cost control through economies of scale [3] Group 4: Future Outlook and Valuation - The company maintains a profit forecast of 178 million yuan, 197 million yuan, and 232 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 0.52, 0.57, and 0.67 yuan [3] - The current stock price corresponds to PE ratios of 28.70, 26.02, and 22.04 for the next three years, indicating a reasonable valuation range compared to peer companies [3] - The company's leading R&D innovation capabilities suggest potential for future valuation expansion [3]

化药业务放量较快增长，生物制品业绩修复 中牧股份(600195) 证券研究报告 动物保健Ⅱ / 公司点评 / 2025.08.28 | 投资评级:增持(维持) | | --- | | 基本数据 | 2025-08-27 | | --- | --- | | 收盘价(元) | 7.58 | | 流通股本(亿股) | 10.21 | | 每股净资产(元) | 5.48 | | 总股本(亿股) | 10.21 | 最近 12 月市场表现 -8% 0% 9% 18% 27% 36% 中牧股份 沪深300 分析师 肖珮菁 SAC 证书编号：S0160524070005 xiaopj@ctsec.com 相关报告 1. 《坚持市场导向战略，业绩有望逐步改 善》 2025-04-29 2. 《业绩 Q3 仍承压，主业有望寻底回升》 2024-10-29 ❖ 事件：公司 1H2025 营收+12.63%，归母净利润+30.19%。公司 2025 年上半年实现营业收入 27.93 亿元（同比+12.63%），归母净利润 0.82 亿元 （同比+30.19%）；单二季度营业收入 15.34 亿元(同比+13.26%)，归母净 利润 ...

Core Viewpoint - The report outlines Wuhan Keqian Bio Co., Ltd.'s commitment to enhancing quality and efficiency while returning value to shareholders through innovation, operational optimization, governance, and investor communication. Group 1: Innovation and Business Development - The company is focusing on strengthening its core competitiveness by expanding into new business areas such as vaccines for ruminants and pets, diagnostic reagents, and insect protein development, achieving a revenue of 487.29 million yuan, a year-on-year increase of 21.67% [1] - Research and development expenses amounted to 45.50 million yuan, with six new veterinary drug certificates obtained and five clinical approvals applied for [2] Group 2: Operational Management and Efficiency - The company has implemented an integrated office approval system and is advancing a new ERP project to enhance operational efficiency and cost management [2] - Inventory strategies have been optimized to accelerate turnover and reduce capital occupation, while accounts receivable management has been strengthened to improve collection efficiency [2][3] Group 3: Governance and Management - The company emphasizes the importance of a sound governance structure and effective internal controls, holding three shareholder meetings and four board meetings in the first half of 2025 [3] - An employee stock ownership plan was implemented, involving 55 key personnel, to align interests between shareholders and employees [3] Group 4: Investor Returns and Communication - Since its listing, the company has maintained a cash dividend policy, distributing a total of 711.10 million yuan from 2020 to 2024, with an average cash dividend ratio of 32.23% [4] - The company has repurchased 2.21 million shares for a total of 35.84 million yuan, reinforcing its commitment to shareholder returns [5] - The company prioritizes timely and transparent information disclosure, having released two regular reports and 69 announcements in the first half of 2025 [5][6]

Core Viewpoint - The A-share market is witnessing a significant increase in mid-year performance disclosures, with over 800 companies reporting revenue growth and more than 700 companies showing an increase in net profit, particularly in the communication equipment sector, which has emerged as a standout performer [2][5][8]. Group 1: Overall Market Performance - As of August 21, over 1,300 listed companies have disclosed their mid-year results, with more than 800 companies achieving revenue growth [2]. - Among these, 88 companies reported revenue growth exceeding 50%, and 23 companies reported growth over 100% [2]. - Over 700 companies reported an increase in net profit, with 16 companies showing a net profit growth rate exceeding 100% [4]. Group 2: Communication Equipment Sector - The communication equipment industry has shown exceptional performance, with over 70% of the 34 companies that disclosed their results reporting revenue and net profit increases [5][7]. - Notably, 25 companies in this sector reported revenue growth, with 6 companies achieving growth rates over 50%, and 16 companies reporting net profit growth exceeding 50% [5]. - The leading company, Shijia Guangzi, reported a revenue of 993 million yuan and a net profit of 217 million yuan, with growth rates of 121.12% and 1712% respectively [5][6]. Group 3: Notable Companies and Their Performance - Haichuang Pharmaceutical, Xianfeng Holdings, and Beijing Culture reported the highest revenue growth rates, with increases of 11899.08%, 2048.03%, and 1944.24% respectively [3][4]. - Xiantian Technology, Dingtong Technology, and Taicheng Light also showed strong performance, with revenue growth rates of 104.99%, 73.51%, and 62.49% respectively [6][8]. Group 4: Market Dynamics and Future Outlook - The growth in the communication equipment sector is driven by the ongoing construction of 5G networks, rapid development of cloud computing and data centers, and trends towards technological upgrades and domestic substitution [7][9]. - The strong performance of companies in this sector has led to a positive correlation between earnings growth and stock price increases, with nearly 80% of companies experiencing stock price rises [8][9]. - The highest stock price increase was observed in Shijia Guangzi, with a rise exceeding 270% year-to-date [8].

Core Insights - The capital market is witnessing a significant performance disclosure season, with over 1,300 listed companies reporting their mid-year results, showing a positive trend in revenue and net profit growth [1][2][3] Group 1: Overall Market Performance - More than 800 companies reported revenue growth, with 88 companies achieving over 50% growth and 23 companies exceeding 100% growth [2] - The top three companies in revenue growth are Haichuang Pharmaceutical, Xianfeng Holdings, and Beijing Culture, with growth rates of 11,899.08%, 2,048.03%, and 1,944.24% respectively [2][3] Group 2: Profitability - Over 700 companies reported an increase in net profit, with 16 companies experiencing growth rates exceeding 1,000% [3] - Leading companies in net profit growth include Xianda Co., Zhimingda, and Rongzhi Rixin, with growth rates above 2,000% [3] Group 3: Communication Equipment Industry - The communication equipment sector stands out with over 70% of companies reporting revenue and net profit increases, significantly outperforming the market average [4][6] - Among 34 listed companies in this sector, 25 reported revenue growth, with 6 companies achieving over 50% growth [4] - Shijia Guangzi leads in both revenue and net profit growth, with revenue of 993 million and net profit of 217 million, reflecting growth rates of 121.12% and 1,712% respectively [4][5] Group 4: Stock Performance - Nearly 80% of communication equipment companies saw their stock prices rise, with the highest increase being over 270% for Shijia Guangzi [7][8] - Companies like Ding Tong Technology and Guangku Technology also reported significant stock price increases of over 120% and approximately 80% respectively [7] - Conversely, companies with declining stock prices often reported poor performance, such as Hainengda and Dongruan Zhaibo, with revenue declines of 17.50% and 9.46% respectively [7] Group 5: Market Drivers - The growth in the communication equipment sector is driven by the ongoing 5G network construction, rapid development of cloud computing and data centers, and trends towards technological upgrades and domestic substitution [6][8]

Core Viewpoint - The report from Open Source Securities indicates that the company is experiencing a significant decline in net profit for the first half of 2025, but maintains a "buy" rating due to strong growth potential from new products and market expansion efforts [1] Financial Performance - The company's net profit attributable to shareholders for the first half of 2025 is 0.60 million yuan, representing a year-over-year decrease of 50.84% [1] - In Q2 2025, the net profit attributable to shareholders is -0.16 million yuan, compared to 0.17 million yuan in Q2 2024 [1] Product Development and Market Expansion - The company is accelerating the research and development of non-epidemic vaccines, with strong growth momentum from new products [1] - Revenue from pig vaccines continues to grow steadily, with non-foot-and-mouth disease products seeing over 20% revenue growth [1] - In the overseas market, the company's sales of pig foot-and-mouth disease vaccines in Vietnam have doubled year-over-year, while actively exploring markets in Mongolia and Central Asia [1] Strategic Initiatives - The company is focused on expanding its market presence and driving long-term performance through major product initiatives [1] - The clinical trial for the mRNA vaccine for feline infectious peritonitis has been approved, along with the registration of new veterinary drugs such as the bovine mycoplasma vaccine (HB150 strain) [1] - The company has a robust pipeline of major products and sufficient reserves of new products, indicating strong growth potential [1]

农林牧渔/动物保健Ⅱ 生物股份（600201.SH） 非瘟疫苗研发加速，新品多点开花成长动能强劲 2025 年 08 月 20 日 投资评级：买入（维持） 日期 2025/8/20 当前股价(元) 9.19 一年最高最低(元) 9.55/5.62 总市值(亿元) 102.17 流通市值(亿元) 102.17 总股本(亿股) 11.12 流通股本(亿股) 11.12 近 3 个月换手率(%) 226.05 股价走势图 -20% 0% 20% 40% 60% 2024-08 2024-12 2025-04 2025-08 生物股份 沪深300 数据来源：聚源 相关研究报告 《非瘟亚单位疫苗临床试验获批，创 新龙头成长动能强劲—公司信息更新 报告》-2025.7.18 《业绩短期承压，持续创新厚积薄发 —公司信息更新报告》-2025.4.27 《业绩短期承压，新品储备充足持续 成长—公司信息更新报告》-2024.11.3 公司猪用疫苗营收保持稳健增长态势，其中猪用非口蹄疫产品营收增长超过 20%，产品结构不断优化。反刍疫苗，牛二联、布病（Rev.1 株）及小反刍兽疫 活疫苗等核心单品放量增长。禽用疫苗，公司组建专属 ...

Group 1 - The report highlights a reversal in the pig farming dilemma, indicating a potential recovery in the industry due to policy-driven capacity adjustments and supply reductions [2][8]. - The current pig cycle is in a de-stocking phase, with the number of breeding sows in China decreasing from a peak of 41.42 million in 2024 to 40.43 million in June 2025, a decline of approximately 2.4% [22][23]. - The Ministry of Agriculture and Rural Affairs has set a target to reduce the breeding sow population by about 1 million heads, aiming for a total of 39.5 million [22][23]. Group 2 - Short-term pig prices are expected to decline due to reduced second fattening and seasonal demand, but a long-term increase is anticipated if the breeding sow population stabilizes below 39.5 million [26][29]. - As of July 25, 2025, the profit from self-breeding pig farming was 62.16 yuan per head, a decrease of 31.61% from the previous week, while the loss from purchasing piglets expanded to 71.39 yuan per head [32][33]. - The report emphasizes that large-scale enterprises will have more stable profitability compared to smallholders due to cost advantages and industry chain synergies [32]. Group 3 - The report identifies two key companies in the pig farming industry: Yongshun Biological and Dayu Biological, detailing their business models and market positions [3][35]. - Yongshun Biological focuses on the research, production, and sales of veterinary biological products, with over 30 types of vaccines for pigs and poultry, maintaining over 90% of its revenue from vaccine sales [3][37]. - Dayu Biological specializes in feed additives and veterinary drugs, with its feed additive and feed businesses accounting for 65.39% and 29.74% of its revenue, respectively [50][56]. Group 4 - The report provides an overview of the pig farming industry chain, which includes upstream breeding, feed production, and veterinary supplies, midstream modern farming practices, and downstream processing and distribution [21][24]. - The entire industry chain is heavily influenced by technological advancements, management practices, disease control, and is subject to environmental regulations and government oversight [21][24].